Only postmenopausal women were selected to participate in this study to eliminate the potential confounding effect of menstrual cycle phase and the potential variability involved in studying both men and women on our metabolic outcome measures. In addition, potential participants who engaged in regular exercise >2 hours/week, consumed more than 20 g of alcohol/day, smoked cigarettes, had a history of allergic reaction or sensitivity to grape products or any component of the treatment compound, or were taking medications known to alter glucose or lipid metabolism were excluded.
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BSA/min for 5 min and then 14 mU/m 2 BSA/min for another 5 min) for 3 h. During stage 2 of the clamp procedure (6.5 to 10 h), the rate of insulin infusion was increased to 50 mU/m 2 BSA/min (initiated with a priming dose of 200 mU/m 2 BSA/min for 5 min and then 100 mU/m 2 BSA/min for another 5 min). These insulin infusion rates were chosen to evaluate liver and adipose tissue insulin sensitivity (low-dose insulin infusion to submaximally suppress glucose production and lipolysis) and skeletal muscle insulin sensitivity (high-dose insulin infusion to stimulate muscle glucose uptake). Euglycemia was maintained at a blood concentration of approximately 5.6 mM (100 mg/dl) by infusing 20% dextrose enriched to 2.5% with [6, H 2 ]glucose. The infusion rate of [6,6-2 H 2 ]glucose was reduced to 50% of basal during stage 1, and to 75% of basal during stage 2 of the clamp procedure to account for the expected decline in endogenous glucose production. The infusion rate of [U- 13 C]palmitate was reduced to 50% of basal during stage 1 to account for the expected decline in lipolytic rate, and was discontinued during stage 2. Resting metabolic rate was determined during the basal period of the clamp procedure, by using a ventilated hood system and metabolic measurement cart (TrueOne 2400 Metabolic Measurement System, Parvo Medics Inc., Yorba Sandy, Utah).
Blood samples were obtained before the start of the tracer infusions to determine plasma resveratrol and dihydroresveratrol concentrations and background plasma glucose and palmitate tracer-to-tracee ratios (TTRs), and every 10 min during the final 30 min of the basal period, and stages 1 and 2 of the clamp procedure to determine glucose and insulin concentrations. Blood samples were collected in chilled tubes, placed on ice, and plasma was separated by centrifugation within 30 min of collection. Plasma samples were stored at -80°C until final analyses were performed.
Skeletal muscle and adipose tissue biopsies
Subcutaneous abdominal adipose tissue and skeletal muscle (vastus lateralis) biopsies were obtained during the basal period of the clamp procedure to investigate the potential molecular events induced by resveratrol supplementation. The biopsy sites were cleaned and draped, and the skin and underlying tissues were anesthetized with lidocaine. A small (~0.5 cm) skin incision was made with a scalpel; adipose tissue was aspirated through a 4 mm liposuction cannula and muscle tissue was obtained by using Tilley-Henkel forceps (Sontec Instruments, Inc., Centennial, CO). Muscle and adipose tissue samples were immediately rinsed in ice-cold saline, frozen in liquid nitrogen and stored at -80°C until final analyses were performed.
Intervention
Capsule production (active and placebo), packaging and labelling were performed at Temmer Werke GmbH (Munich, Germany). During the intervention period, one capsule was taken every day in the morning with breakfast. Supplementation was started the day after the baseline visit and ended the morning of the day of the final clamp procedure, 12 weeks after the baseline visit. Each subject in the placebo and resveratrol groups had 11 visits (pre-study examination, 2 baseline visits, 6 interim visits every two weeks, 2 final visits). They were instructed to maintain their normal diet and physical activity. Subjects were seen weekly to review any study-related issues and reinforce supplementation compliance. Subjects randomized to the calorie restriction weight loss group participated in a lifestyle therapy program that focused on reducing calorie intake without changing physical activity. This program involved weekly (~1 h long) dietary and behavioral education sessions led by an experienced weight management dietician. The recommended daily calorie intake during the weight loss intervention was 30% less than the estimated subject-specific total daily energy expenditure at baseline (i.e., 1.65 x resting metabolic rate measured during the basal period of the baseline hyperinsulinemic-euglycemic clamp procedure (Votruba et al., 2002) .
Sample processing and analyses
Plasma glucose concentration was determined by using an automated glucose analyzer (YSI 2300 STAT Plus, Yellow Springs Instruments Co., Yellow Springs, OH). Plasma free fatty acid (FFA) concentrations were quantified by using gas chromatography (HP 5890 Series II GC; Hewlett-Packard, Palo Alto, CA). Plasma insulin concentration was measured by using a chemiluminescent immunometric assay (Immulite 1000; Diagnostic Products Corp, Los Angeles, CA). Plasma CRP, IL-6, leptin and adiponectin concentrations were measured by using commercially available high-sensitivity ELISA kits. Total resveratrol and dihydroresveratrol concentrations (both free and conjugated forms) were determined by using liquid chromatography-mass spectrometry. Plasma glucose and palmitate tracer-to-tracee ratios (TTRs) were determined by using gas chromatography/mass spectroscopy (MSD 5973 system with capillary column), as previously described (Patterson et al., 1998) . Plasma chemistries and lipids (total cholesterol, LDL-cholesterol, triglyceride, HDL-cholesterol) were determined by using certified clinical laboratories according to clinically accepted standardized analytical protocols.
Real time PCR
Total RNA was isolated from frozen muscle and adipose tissue samples. Real-time PCR was performed using the 7900HT Fast Real-Time PCR System (Applied Biosystems) as previously reported (Yoshino et al., 2011) . To determine the mRNA expression of putative resveratrol targets, the TaqMan gene expression assays were used: Human GAPD (GAPDH) Endogenous Control (4333764), Human PPARGC1A (Assay ID Hs01016719_m1), Human NAMPT (Assay ID Hs00237184_m1), Human SIRT1 (Assay ID Hs01009005_m1), and Human UCP3 (Assay ID Hs01106052_m1). Relative expression levels were determined based on the (cycle threshold) (CT) values and normalized to CT values for the GAPDH gene.
Outlier CT values were excluded by using the Grubbs-Smirnov test (p < 0.01).
Microarray and bioinformatics analyses
Global gene expression profiles were assessed by using Affymetrix Human Genome U133 Plus 2.0 array gene chips. Gene expression microarray data were analyzed by using using R/Bioconductor. The quality of all expression microarray data were examined for comparable scale factor, similar average background and percent present calls, and RNA integrity using R package 'simpleaffy'. All "house-keeping" genes used by Affymetrix for on-chip quality control were removed from further analysis and those with "absent" calls on all arrays were flagged. Background correction and quantile normalization were applied by using the robust multi-array average (RMA) method in R package 'affy' to derive summary expression levels for further analysis.
To detect genes that are significantly differentially expressed before and after each supplementation, we applied the method of significance analysis of microarrays (SAM) (Tusher et al., 2001) implemented in the R package 'siggenes'. For each gene, "relative differences", compared to a large number of random controls, were generated by permutations of the observed data. Significant genes were identified with their relative differences displaced from the expected values over a threshold of Δ (=0.4). The expected number of falsely called genes was estimated by averaging, over every permutation, the numbers of genes that had relative differences more extreme than the observed values of the significant ones. The corresponding false discovery rate (FDR) was calculated for the gene list.
To reduce chance of false negatives, we also applied the gene set enrichment analysis (GSEA) to examine collective effects of multiple genes in known pathways using a GSEA package from the Broad Institute. A collection of ~2100 gene sets derived from GO, BioCarta, KEGG, and REACTOME databases were tested for possible enrichment of differentially expressed genes in each group. A threshold of FDR of ≤ 25% (0.25) was used to identify potentially significant gene sets.
All microarray data used in this study have been deposited into the NCBI GEO database (Accession number: GSE41168).
Western blotting
Muscle protein extract (30 μg) was analyzed by western blotting with an anti-phospho-AMPKα (Thr172) antibody (Cell Signaling Technology, #2531). The same blot was reprobed with anti-AMPKα antibody (Cell Signaling Technology, #2532). After incubation with a HRP-linked anti-rabbit antibody (Cell Signaling, #7074), signals were visualized using the ECL Prime detection reagent (Amersham).
Skeletal muscle and adipose tissue samples were not available in all subjects for all analyses; real-time PCR was used to analyze tissue from 9-12 subjects per group, microarray analysis was used to analyze tissue from 9-14 subjects per group, and western blotting was used to analyze tissue from 4 subjects per group.
Calculations
The homeostasis model assessment of insulin resistance (HOMA-IR) score was calculated as previously described (Matthews et al., 1985) . Isotopic steady state conditions were achieved during the final 30 min of the basal period and stages 1 and 2 of the clamp procedure, so Steele's equation for steady-state conditions was used to calculate glucose and palmitate R a and glucose R d (Steele, 1959) . The hepatic insulin sensitivity index was determined as the reciprocal of the hepatic insulin resistance index, calculated as the product of the basal hepatic glucose production rate (in μmol/min) and basal plasma insulin concentration (in μU/ml) (Matsuda and DeFronzo, 1999) . Liver and adipose tissue insulin sensitivity were assessed by calculating the decrease from basal in glucose R a and palmitate R a during stage 1 of the clamp procedure. Skeletal muscle insulin sensitivity was assessed by calculating the increase above basal in glucose R d during stage 2 of the clamp procedure.
Based on our experience in the intra-individual variability of glucose kinetics during insulin infusion (Magkos et al., 2011) , we estimated that a sample size of 15 subjects per group would give us a power of 80% (beta=0.2) at an alpha value of 0.05 for two-sided tests to detect a 25% increase in skeletal muscle insulin sensitivity (increase in glucose R d ) in subjects treated with resveratrol compared with placebo.
Tolerability Assessment
All adverse events (AEs) were classified as mild, moderate, or severe. Of the total of 85 AEs that occurred in 26 subjects, 35 were reported in 11 subjects in the placebo group and 50 were reported in 15 subjects in the resveratrol group. None of the AEs led to withdrawal from the study; 46% of AEs in the placebo group and 40% of AEs in the resveratrol group were treated. One AE in the resveratrol group was classified as serious (a transient ischemic attack which was considered unrelated to therapy), 83% of AEs in the placebo group and 72% of AEs in the resveratrol group were considered moderate, and 17.1% of AEs in the placebo group and 28% of AEs in the resveratrol group were considered mild. All AEs were judged to be unrelated to resveratrol supplementation. Although AEs were distributed over a wide range of system organ classes, most were "gastrointestinal disorders" (10 AEs in 4 placebo subjects and 12 AEs in 8 resveratrol subjects; most of the gastrointestinal AEs were "nausea" and "vomiting") and "nervous system disorders" (6 AEs in 4 placebo subjects and 11 AEs in 9 resveratrol subjects; most of the nervous system AEs were "headache" and "dizziness"). Figure 2C . The arrow on the left identifies phosphorylated AMPKα (Thr172) and total AMPKα in skeletal muscle obtained from 4 subjects (#1-4) before (B) and after (A) resveratrol supplementation. 13.6 ± 0.7 12.8 ± 0.6 13.4 ± 1.1 12.5 ± 0.8 Hematocrit (%) 38.9 ± 2.5 36.3 ± 1.8 38.8 ± 3.3 35.8 ± 2.6 MCV (fl) 90.3 ± 2.5 89.3 ± 2.7 89.4 ± 3.6 89.2 ± 3.9 MCH (pg) 31.5 ± 1.2 31.5 ± 0.9 30.8 ± 1.5 31.2 ± 1.7 MCHC (g/dl) 34.9 ± 0.7 35.3 ± 0.4 34.5 ± 0.8 35.0 ± 0.8 Sodium (mmol/l) 142 ± 1 140 ± 2 140 ± 1 140 ± 1 Potassium (mmol/l) 3.9 ± 0.3 4.0 ± 0.3 3.9 ± 0.3 3.9 ± 0.4 Choloride (mmol/l) 104 ± 1 106 ± 3 104 ± 2 106 ± 2 Calcium (mg/dl) 9.3 ± 0. Values are means ± SD. LDL, low-density lipoprotein; HDL, high-density lipoprotein; FFM, fat-free mass; HISI, hepatic insulin sensitivity index; HOMA-IR, homeostasis model assessment of insulin resistance. *Effect of Calorie Restriction (change from Before value) significantly different than the effect of placebo or resveratrol supplementation, evaluated by using Analysis of Covariance (ANCOVA) to compare the differences in post-intervention outcome measures among the placebo, resveratrol and calorie restriction groups, and post-hoc tests with Bonferroni correction, p≤0.05.
